Enjoy complimentary customisation on priority with our Enterprise License!
The global sjogrens syndrome therapeutics market size is estimated to grow by USD 691.09 million at a CAGR of 6.53% between 2022 and 2027.
The global sjogrens syndrome therapeutics market is a niche market. Though the main cause of Sjogren's syndrome is unknown, scientists believe that it is mostly caused due to autoimmune diseases such as rheumatoid arthritis and lupus. In order to treat the disease, there are several medicines available. With the strong pipeline and rising awareness about the syndrome, some drugs are likely to be approved through various initiatives and programs undertaken by companies during the forecast period. The aim is to obtain the patient's opinion so that approval can be obtained. To ensure that patients' perspectives were included in the trial design, the diversity and patient engagement team established Sjogren's Patient Engagement Network (PEN).
Technavio has segmented the market into Application, Type, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
Clinical
The market share growth by the clinical segment will be significant during the forecast period. Market segmentation, also known as application segmentation, is a method of identifying different customer segments with unique needs and preferences in the context of a larger market. In the context of the global market for sjogrens syndrome therapeutics, this segmentation allows for product and service adjustments based on the specific clinical application needs of pharmaceutical companies and healthcare providers.
Get a glance at the market contribution of various segments View a PDF Sample
The clinical segment was valued at USD 991.80 million in 2017. Clinical therapeutics are also available to address the muscular-skeletal manifestations of sjogrens syndrome. This autoimmune condition can have a wide range of effects on tissues and structures, such as joints, muscles, and connective tissue, resulting in symptoms such as joint pain, muscle stiffness, and arthritis. Therefore, it is essential to provide tailored treatments for the improvement of mobility, comfort, and optimal functioning in response to these symptoms. These mentioned clinical uses will expand the growth of the global Sjorgens syndrome therapeutics market during the forecast period.
Primary Sjogrens
The primary sjogrens syndrome segment is a major segment of the global Sjogrens therapeutics market. Primary sjogrens syndrome is a systematic autoimmune disorder of the exocrine glands. The common symptoms include dryness in the mouth and eyes. Primary sjogrens syndrome is more prevalent among women than men. Women also experience dryness in the vagina. The symptoms are known as sicca symptoms, including xerophthalmia (dry eyes) and xerostomia (dry mouth). Although there are treatments available in the market for sicca symptoms, there is currently no cure for the condition. All these symptoms lead to a higher demand for Sjorgens syndrome therapeutics and thereby increase the growth of the market in focus.
Secondary Sjogrens
Secondary sjogrens syndrome is associated with other autoimmune disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and connective tissue diseases. Its symptoms are mainly the same as primary Sjogren's syndrome, known as sicca symptom. sjogrens syndrome is the second-most common rheumatic autoimmune disorder after RA and SLE. The market has witnessed the development of symptomatic treatments in clinical trials, which will drive the market in focus growth during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. The growing incidence of autoimmune disorders drives the sjogrens syndrome therapeutics market in North America due to changing lifestyles such as taking a low-fat diet. According to the Centers for Disease Control and Prevention (CDC), autoimmune diseases are the third most common category in the US. It is also known that the majority of trials in developing treatment for Sjogren's Syndrome are carried out in Northern America. This will drive the growth of the sjogrens syndrome therapeutics market in North America. During the forecast period, upcoming approvals of therapeutic candidates by the US FDA (Food and Drug Administration)will drive market growth in the region.
The coronavirus pandemic of 2020 had a major influence on the North American sjogrens syndrome therapeutics market. The pandemic has resulted in restrictions, lockdowns, and reduced production capacity from March 2020, which is delaying the availability of Sjogren's syndrome medicines due to shortages in supply. Furthermore, patients have encountered difficulties in obtaining the necessary medications, resulting in heightened anxieties and a decrease in overall market demand.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
ADVANZ PHARMA Corp. - The company offers sjogrens syndrome therapeutics such as a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, and endocrinology.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The high prevalence and incidence of Sjogren's syndrome is driving growth in the sjogrens syndrome therapeutics market. Sjogren's Syndrome is a condition that can be associated with other immune disorders, for example, rheumatoid arthritis and lupus. The condition is more common in women than men. The incidence of sjogrens syndrome is rising globally. sjogrens syndrome is not fatal.
However, if it is left untreated, people can develop lymphoma, which can result in dental cavities, yeast infections, and vision problems. Due to changes in lifestyle and dietary habits, the prevalence of this disease is increasing. The prevalence of sjogrens syndrome depends on SLE. The high prevalence of sjogrens syndrome is expected to boost the market growth during the forecast period.
The rising number of awareness programs is a key trend in the sjogrens syndrome therapeutics market. The Sjogren's Syndrome is currently the most common disease in the world. Dry mouth is not a trivial symptom for sjogrens syndrome patients as it has a considerable impact on their daily lives. Dry eye is one of the most common early symptoms of the disease.
There is an increase in efforts to educate eye care providers to identify and be aware of disease symptoms. When patients talk to their doctors about potential medical diagnostics and treatments, they also need to be informed and ready for action. Many organizations are focusing on increasing the awareness of sjogrens syndrome. Awareness programs will drive the global sjogrens syndrome therapeutics market during the forecast period.
The unwanted immunogenicity of therapeutic antigens is a major challenge in the sjogrens syndrome therapeutics market. Undesirable immunogenicity occurs when the body's immune system responds to a therapeutic antigen. This reaction leads to the production of anti-drug antibodies (ADAs) that inactivate the therapeutic effects of the treatment. In rare cases, they can induce adverse effects. Immunogenicity is a major factor that can limit the use of therapeutics, which may hinder market growth. Immunosuppression, which may lead to opportunistic infections, is caused by the use of biologics.
Moreover, in order to treat rheumatoid arthritis, there is an increase in the introduction and use of biotherapeutics. The formation of immune complexes between ADAs and biologics may result in clearance, reduce serum biologic levels, and may have a more direct neutralizing effect on product-target binding. Such adverse effects can result in low patient compliance. This is eventually expected to hinder the growth of the global sjogrens syndrome therapeutics market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Sjogrens Syndrome Therapeutics Market Customer Landscape
The sjogrens syndrome therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Sjogrens Syndrome Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
156 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.53% |
Market growth 2023-2027 |
USD 691.09 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.51 |
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., ADVANZ PHARMA Corp., Biogen Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Johnson and Johnson, MorphoSys AG, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., RemeGen Ltd., Resolve Therapeutics LLC, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and TearSolutions Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.